Лечащий Врач (May 2024)
Evaluation of efficacy and adherence to treatment of patients with osteoarthritis with structure-modifying drug of SYSADOA group
Abstract
Objective. The purpose of the study was to evaluate the effectiveness of a 20-day course of injectable chondroprotector in patients with osteoarthritis in extremity joints and nonspecific lower back pain in clinical practice.Materials and methods. The study included 78 outpatients, aged 25 to 80 years (27 men and 51 women; mean age 50.0 [45.0; 58.0] years), who sought consultation with a neurologist for exacerbated osteoarthritis in extremity joints and lower back pain. The effectiveness of therapy was evaluated using the visual analog scales (VAS) based on the severity of pain, the patient's self-assessment of health, quality of life and the patient's adherence to therapy. The time of onset of the therapeutic effect and whether the patient needed to take NSAIDs were recorded. The EQ-5D quality of life questionnaire was used to assess the patient's general health and its components: mobility, ability to self-care, activities of daily living, presence of pain and/or discomfort, anxiety and/or depression.Results. Statistical analysis of the survey results using visual analogue scales showed a decrease in pain intensity from 70.0 [10.0; 90.0] to 12.5 [0.0; 70.0]; health assessment improved from 50.0 [0.0; 90.0] to 90.0 [20.0; 100]; and satisfaction with the therapy increased from 30.0 [0.0; 90.0] to 90.0 [20.0; 100]. Positive dynamics were observed in all EQ-5D questionnaire categories after 20 days of treatment, with statistically significant improvements in health levels from the start to the end of the therapy course (p < 0.05). All 78 patients (100%) completed the entire course therapy. Out of these, 74 patients responded positively to the treatment, while 4 patients reported no changes in their condition.Conclusion. The therapy has shown effectiveness in treating pain in patients with osteoarthritis of extremity joints and the lumbar spine. During the course of therapy, no deterioration in somatic condition, drug intolerance, or complications from comorbid diseases were observed. The therapeutic effect of a 20-day course was observed in the majority of subjects by the middle of the treatment course. Additionally, the use of injectable chondroprotector allowed for a reduction in the dose of NSAIDs taken.
Keywords
